Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidanc...( FOSRENOL 42.4 ...)

FOSRENOL 42.4 73% -4% 8.2%

XAGRID 20.6 20% n/a n/a

Human Genetic Therapies

ELAPRASE 80.8 89% n/a n/a

REPLAGAL 44.7 40% n/a n/a

(1) Product specific prescription data is provided by IMS Health

("IMS"), a leading global provider of business intelligence for the

pharmaceutical and healthcare industries. All other US market share

data stated in the text below is also provided by IMS.

(2) Compared to Q2 2007.

Specialty Pharmaceuticals

US ADHD market share Shire's average quarterly market share of the US ADHD market rose to 32.3% in the three months to June 30, 2008 (2007: 28.6%), driven by the introduction of VYVANSE in July 2007. The overall US ADHD market grew by 7% in the same period. Shire has the leading portfolio of products in the US ADHD market.

ADDERALL XR - ADHD

As a result of the launch of VYVANSE in July 2007, ADDERALL XR's average quarterly market share of the US ADHD market for Q2 2008 fell to 23.1% (2007: 26.3%), a decrease of 12% compared to Q2 07. US prescriptions for ADDERALL XR for the period to June 30, 2008 decreased by 6% compared to the same period in 2007 due to the 12% decrease in average market share offset by 7% growth in the US ADHD market.

Sales of ADDERALL XR for the three months to June 30, 2008 were $296.4 million, an increase of 16% compared to the same period in 2007 (2007: $255.1 million). Product sales grew despite the decline in US prescriptions primarily due to price increases in October 2007 and April 2008.

Litigation proceedings concerning Shire's ADDERALL XR patents are ongoing. Further information on this litigation can be found in our filings with the US Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for th
'/>"/>